nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—SLC6A4—chronic obstructive pulmonary disease	0.159	0.373	CbGaD
Ziprasidone—CYP1A2—chronic obstructive pulmonary disease	0.145	0.34	CbGaD
Ziprasidone—HTR2A—chronic obstructive pulmonary disease	0.123	0.287	CbGaD
Ziprasidone—CHRM5—Tiotropium—chronic obstructive pulmonary disease	0.0778	0.241	CbGbCtD
Ziprasidone—CHRM3—Tiotropium—chronic obstructive pulmonary disease	0.0497	0.154	CbGbCtD
Ziprasidone—CHRM1—Tiotropium—chronic obstructive pulmonary disease	0.0432	0.134	CbGbCtD
Ziprasidone—CHRM2—Tiotropium—chronic obstructive pulmonary disease	0.0399	0.123	CbGbCtD
Ziprasidone—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0168	0.0521	CbGbCtD
Ziprasidone—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0163	0.0505	CbGbCtD
Ziprasidone—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0163	0.0505	CbGbCtD
Ziprasidone—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0145	0.045	CbGbCtD
Ziprasidone—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0137	0.0423	CbGbCtD
Ziprasidone—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.00924	0.0286	CbGbCtD
Ziprasidone—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.00882	0.0273	CbGbCtD
Ziprasidone—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00786	0.0243	CbGbCtD
Ziprasidone—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.00506	0.194	CbGeAlD
Ziprasidone—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00461	0.0143	CbGbCtD
Ziprasidone—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00435	0.0135	CbGbCtD
Ziprasidone—HTR7—pulmonary artery—chronic obstructive pulmonary disease	0.00294	0.113	CbGeAlD
Ziprasidone—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00184	0.0705	CbGeAlD
Ziprasidone—Lurasidone—HTR2A—chronic obstructive pulmonary disease	0.00129	0.395	CrCbGaD
Ziprasidone—H1F0—respiratory system—chronic obstructive pulmonary disease	0.000802	0.0308	CbGeAlD
Ziprasidone—HTR3A—respiratory system—chronic obstructive pulmonary disease	0.000765	0.0294	CbGeAlD
Ziprasidone—H1F0—connective tissue—chronic obstructive pulmonary disease	0.000706	0.0271	CbGeAlD
Ziprasidone—H1F0—bronchus—chronic obstructive pulmonary disease	0.00066	0.0254	CbGeAlD
Ziprasidone—H1F0—smooth muscle tissue—chronic obstructive pulmonary disease	0.000646	0.0248	CbGeAlD
Ziprasidone—H1F0—trachea—chronic obstructive pulmonary disease	0.000593	0.0228	CbGeAlD
Ziprasidone—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.000584	0.0224	CbGeAlD
Ziprasidone—HTR1D—connective tissue—chronic obstructive pulmonary disease	0.000547	0.021	CbGeAlD
Ziprasidone—HTR7—respiratory system—chronic obstructive pulmonary disease	0.000495	0.019	CbGeAlD
Ziprasidone—DRD2—respiratory system—chronic obstructive pulmonary disease	0.000468	0.018	CbGeAlD
Ziprasidone—HTR7—connective tissue—chronic obstructive pulmonary disease	0.000436	0.0168	CbGeAlD
Ziprasidone—CHRM1—trachea—chronic obstructive pulmonary disease	0.00043	0.0165	CbGeAlD
Ziprasidone—H1F0—lung—chronic obstructive pulmonary disease	0.000426	0.0164	CbGeAlD
Ziprasidone—CHRM3—smooth muscle tissue—chronic obstructive pulmonary disease	0.000419	0.0161	CbGeAlD
Ziprasidone—HTR3A—lung—chronic obstructive pulmonary disease	0.000406	0.0156	CbGeAlD
Ziprasidone—Aripiprazole—SLC6A4—chronic obstructive pulmonary disease	0.000402	0.123	CrCbGaD
Ziprasidone—Trazodone—SLC6A4—chronic obstructive pulmonary disease	0.0004	0.122	CrCbGaD
Ziprasidone—HTR7—smooth muscle tissue—chronic obstructive pulmonary disease	0.000399	0.0153	CbGeAlD
Ziprasidone—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000395	0.0152	CbGeAlD
Ziprasidone—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000381	0.0146	CbGeAlD
Ziprasidone—ADRA2C—bronchus—chronic obstructive pulmonary disease	0.000375	0.0144	CbGeAlD
Ziprasidone—HRH1—respiratory system—chronic obstructive pulmonary disease	0.00037	0.0142	CbGeAlD
Ziprasidone—HTR7—trachea—chronic obstructive pulmonary disease	0.000366	0.0141	CbGeAlD
Ziprasidone—ADRA2C—trachea—chronic obstructive pulmonary disease	0.000336	0.0129	CbGeAlD
Ziprasidone—HRH1—connective tissue—chronic obstructive pulmonary disease	0.000325	0.0125	CbGeAlD
Ziprasidone—ADRA2A—connective tissue—chronic obstructive pulmonary disease	0.00032	0.0123	CbGeAlD
Ziprasidone—SLC6A4—lung—chronic obstructive pulmonary disease	0.00031	0.0119	CbGeAlD
Ziprasidone—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000309	0.0119	CbGeAlD
Ziprasidone—CHRM1—lung—chronic obstructive pulmonary disease	0.000309	0.0119	CbGeAlD
Ziprasidone—Aripiprazole—HTR2A—chronic obstructive pulmonary disease	0.000309	0.0942	CrCbGaD
Ziprasidone—Trazodone—HTR2A—chronic obstructive pulmonary disease	0.000307	0.0937	CrCbGaD
Ziprasidone—ADRA2A—bronchus—chronic obstructive pulmonary disease	0.000299	0.0115	CbGeAlD
Ziprasidone—HRH1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000298	0.0114	CbGeAlD
Ziprasidone—HRH1—trachea—chronic obstructive pulmonary disease	0.000273	0.0105	CbGeAlD
Ziprasidone—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000272	0.0104	CbGeAlD
Ziprasidone—ADRA2A—trachea—chronic obstructive pulmonary disease	0.000268	0.0103	CbGeAlD
Ziprasidone—HTR7—lung—chronic obstructive pulmonary disease	0.000263	0.0101	CbGeAlD
Ziprasidone—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000249	0.00956	CbGeAlD
Ziprasidone—DRD2—lung—chronic obstructive pulmonary disease	0.000249	0.00955	CbGeAlD
Ziprasidone—ADRA2C—lung—chronic obstructive pulmonary disease	0.000242	0.00929	CbGeAlD
Ziprasidone—HTR2A—trachea—chronic obstructive pulmonary disease	0.000228	0.00877	CbGeAlD
Ziprasidone—CYP1A2—lung—chronic obstructive pulmonary disease	0.00021	0.00806	CbGeAlD
Ziprasidone—Clozapine—CYP1A1—chronic obstructive pulmonary disease	0.000204	0.0622	CrCbGaD
Ziprasidone—CYP3A5—lung—chronic obstructive pulmonary disease	0.000202	0.00777	CbGeAlD
Ziprasidone—Clozapine—CYP1A2—chronic obstructive pulmonary disease	0.000197	0.06	CrCbGaD
Ziprasidone—HRH1—lung—chronic obstructive pulmonary disease	0.000196	0.00754	CbGeAlD
Ziprasidone—ADRA2A—lung—chronic obstructive pulmonary disease	0.000193	0.00741	CbGeAlD
Ziprasidone—Clozapine—HTR2A—chronic obstructive pulmonary disease	0.000166	0.0506	CrCbGaD
Ziprasidone—HTR2A—lung—chronic obstructive pulmonary disease	0.000164	0.0063	CbGeAlD
Ziprasidone—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000921	CcSEcCtD
Ziprasidone—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000132	0.00092	CcSEcCtD
Ziprasidone—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000132	0.00092	CcSEcCtD
Ziprasidone—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.000919	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000132	0.000918	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000132	0.000918	CcSEcCtD
Ziprasidone—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000917	CcSEcCtD
Ziprasidone—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000906	CcSEcCtD
Ziprasidone—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00013	0.000905	CcSEcCtD
Ziprasidone—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00013	0.000905	CcSEcCtD
Ziprasidone—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00013	0.000904	CcSEcCtD
Ziprasidone—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00013	0.000904	CcSEcCtD
Ziprasidone—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00013	0.000902	CcSEcCtD
Ziprasidone—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000901	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000129	0.000899	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000129	0.000897	CcSEcCtD
Ziprasidone—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.000894	CcSEcCtD
Ziprasidone—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000885	CcSEcCtD
Ziprasidone—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000883	CcSEcCtD
Ziprasidone—Infection—Formoterol—chronic obstructive pulmonary disease	0.000127	0.00088	CcSEcCtD
Ziprasidone—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000127	0.00088	CcSEcCtD
Ziprasidone—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.000872	CcSEcCtD
Ziprasidone—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.000872	CcSEcCtD
Ziprasidone—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.000872	CcSEcCtD
Ziprasidone—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000126	0.000872	CcSEcCtD
Ziprasidone—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.000869	CcSEcCtD
Ziprasidone—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000125	0.000869	CcSEcCtD
Ziprasidone—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.000869	CcSEcCtD
Ziprasidone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000125	0.000868	CcSEcCtD
Ziprasidone—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.000864	CcSEcCtD
Ziprasidone—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000124	0.000864	CcSEcCtD
Ziprasidone—Infection—Montelukast—chronic obstructive pulmonary disease	0.000124	0.000862	CcSEcCtD
Ziprasidone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000124	0.00086	CcSEcCtD
Ziprasidone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.00086	CcSEcCtD
Ziprasidone—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000123	0.000857	CcSEcCtD
Ziprasidone—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.000853	CcSEcCtD
Ziprasidone—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000852	CcSEcCtD
Ziprasidone—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000123	0.000851	CcSEcCtD
Ziprasidone—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000122	0.000849	CcSEcCtD
Ziprasidone—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000848	CcSEcCtD
Ziprasidone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000121	0.000843	CcSEcCtD
Ziprasidone—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.000831	CcSEcCtD
Ziprasidone—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.000828	CcSEcCtD
Ziprasidone—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000119	0.000828	CcSEcCtD
Ziprasidone—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.000823	CcSEcCtD
Ziprasidone—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.000822	CcSEcCtD
Ziprasidone—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.00082	CcSEcCtD
Ziprasidone—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000819	CcSEcCtD
Ziprasidone—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.000816	CcSEcCtD
Ziprasidone—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000815	CcSEcCtD
Ziprasidone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.000812	CcSEcCtD
Ziprasidone—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000116	0.000809	CcSEcCtD
Ziprasidone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.000809	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000116	0.000807	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000116	0.000807	CcSEcCtD
Ziprasidone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000115	0.000801	CcSEcCtD
Ziprasidone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000115	0.000801	CcSEcCtD
Ziprasidone—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000115	0.000797	CcSEcCtD
Ziprasidone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000115	0.000796	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000114	0.00079	CcSEcCtD
Ziprasidone—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000114	0.00079	CcSEcCtD
Ziprasidone—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000114	0.00079	CcSEcCtD
Ziprasidone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000113	0.000787	CcSEcCtD
Ziprasidone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000113	0.000787	CcSEcCtD
Ziprasidone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000113	0.000785	CcSEcCtD
Ziprasidone—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.000782	CcSEcCtD
Ziprasidone—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.00078	CcSEcCtD
Ziprasidone—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000112	0.00078	CcSEcCtD
Ziprasidone—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000112	0.000779	CcSEcCtD
Ziprasidone—Injury—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000772	CcSEcCtD
Ziprasidone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000111	0.000771	CcSEcCtD
Ziprasidone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000111	0.00077	CcSEcCtD
Ziprasidone—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.000768	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00011	0.000765	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.000765	CcSEcCtD
Ziprasidone—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00011	0.000764	CcSEcCtD
Ziprasidone—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00011	0.000764	CcSEcCtD
Ziprasidone—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.000764	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00011	0.000762	CcSEcCtD
Ziprasidone—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000109	0.000757	CcSEcCtD
Ziprasidone—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000109	0.000757	CcSEcCtD
Ziprasidone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000109	0.000756	CcSEcCtD
Ziprasidone—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000755	CcSEcCtD
Ziprasidone—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000755	CcSEcCtD
Ziprasidone—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000108	0.000751	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000108	0.000749	CcSEcCtD
Ziprasidone—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000108	0.000748	CcSEcCtD
Ziprasidone—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000107	0.000746	CcSEcCtD
Ziprasidone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000107	0.000744	CcSEcCtD
Ziprasidone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000107	0.00074	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000737	CcSEcCtD
Ziprasidone—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.000736	CcSEcCtD
Ziprasidone—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000106	0.000734	CcSEcCtD
Ziprasidone—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000106	0.000733	CcSEcCtD
Ziprasidone—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.000731	CcSEcCtD
Ziprasidone—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000105	0.00073	CcSEcCtD
Ziprasidone—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000105	0.00073	CcSEcCtD
Ziprasidone—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000105	0.000729	CcSEcCtD
Ziprasidone—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.000727	CcSEcCtD
Ziprasidone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000104	0.000726	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000104	0.000724	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000104	0.000724	CcSEcCtD
Ziprasidone—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000724	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.000722	CcSEcCtD
Ziprasidone—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.000721	CcSEcCtD
Ziprasidone—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000715	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000102	0.000709	CcSEcCtD
Ziprasidone—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000709	CcSEcCtD
Ziprasidone—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000101	0.000704	CcSEcCtD
Ziprasidone—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.000704	CcSEcCtD
Ziprasidone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000101	0.0007	CcSEcCtD
Ziprasidone—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000101	0.0007	CcSEcCtD
Ziprasidone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.0007	CcSEcCtD
Ziprasidone—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.0007	CcSEcCtD
Ziprasidone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.0001	0.000698	CcSEcCtD
Ziprasidone—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	9.97e-05	0.000693	CcSEcCtD
Ziprasidone—Rash—Tiotropium—chronic obstructive pulmonary disease	9.96e-05	0.000692	CcSEcCtD
Ziprasidone—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	9.95e-05	0.000691	CcSEcCtD
Ziprasidone—Nausea—Aminophylline—chronic obstructive pulmonary disease	9.95e-05	0.000691	CcSEcCtD
Ziprasidone—Urticaria—Montelukast—chronic obstructive pulmonary disease	9.92e-05	0.000689	CcSEcCtD
Ziprasidone—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	9.92e-05	0.000689	CcSEcCtD
Ziprasidone—Headache—Tiotropium—chronic obstructive pulmonary disease	9.9e-05	0.000688	CcSEcCtD
Ziprasidone—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	9.9e-05	0.000687	CcSEcCtD
Ziprasidone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	9.87e-05	0.000686	CcSEcCtD
Ziprasidone—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	9.87e-05	0.000686	CcSEcCtD
Ziprasidone—Face oedema—Prednisone—chronic obstructive pulmonary disease	9.86e-05	0.000685	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	9.85e-05	0.000684	CcSEcCtD
Ziprasidone—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	9.77e-05	0.000679	CcSEcCtD
Ziprasidone—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	9.72e-05	0.000675	CcSEcCtD
Ziprasidone—Urticaria—Salbutamol—chronic obstructive pulmonary disease	9.57e-05	0.000664	CcSEcCtD
Ziprasidone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	9.52e-05	0.000661	CcSEcCtD
Ziprasidone—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	9.52e-05	0.000661	CcSEcCtD
Ziprasidone—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	9.4e-05	0.000653	CcSEcCtD
Ziprasidone—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	9.4e-05	0.000653	CcSEcCtD
Ziprasidone—Nausea—Tiotropium—chronic obstructive pulmonary disease	9.39e-05	0.000652	CcSEcCtD
Ziprasidone—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	9.37e-05	0.000651	CcSEcCtD
Ziprasidone—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	9.29e-05	0.000645	CcSEcCtD
Ziprasidone—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	9.2e-05	0.000639	CcSEcCtD
Ziprasidone—Asthenia—Formoterol—chronic obstructive pulmonary disease	9.15e-05	0.000636	CcSEcCtD
Ziprasidone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	9.15e-05	0.000636	CcSEcCtD
Ziprasidone—Asthenia—Montelukast—chronic obstructive pulmonary disease	8.96e-05	0.000622	CcSEcCtD
Ziprasidone—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	8.87e-05	0.000616	CcSEcCtD
Ziprasidone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	8.73e-05	0.000606	CcSEcCtD
Ziprasidone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	8.73e-05	0.000606	CcSEcCtD
Ziprasidone—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	8.68e-05	0.000603	CcSEcCtD
Ziprasidone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	8.64e-05	0.0006	CcSEcCtD
Ziprasidone—Sweating increased—Prednisone—chronic obstructive pulmonary disease	8.6e-05	0.000597	CcSEcCtD
Ziprasidone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	8.55e-05	0.000594	CcSEcCtD
Ziprasidone—Erythema—Prednisolone—chronic obstructive pulmonary disease	8.46e-05	0.000588	CcSEcCtD
Ziprasidone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	8.43e-05	0.000586	CcSEcCtD
Ziprasidone—Dizziness—Formoterol—chronic obstructive pulmonary disease	8.43e-05	0.000586	CcSEcCtD
Ziprasidone—Dizziness—Montelukast—chronic obstructive pulmonary disease	8.26e-05	0.000574	CcSEcCtD
Ziprasidone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	8.24e-05	0.000572	CcSEcCtD
Ziprasidone—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	8.13e-05	0.000565	CcSEcCtD
Ziprasidone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	8.11e-05	0.000563	CcSEcCtD
Ziprasidone—Vomiting—Formoterol—chronic obstructive pulmonary disease	8.11e-05	0.000563	CcSEcCtD
Ziprasidone—Rash—Formoterol—chronic obstructive pulmonary disease	8.04e-05	0.000558	CcSEcCtD
Ziprasidone—Rash—Arformoterol—chronic obstructive pulmonary disease	8.04e-05	0.000558	CcSEcCtD
Ziprasidone—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	8.03e-05	0.000558	CcSEcCtD
Ziprasidone—Dermatitis—Formoterol—chronic obstructive pulmonary disease	8.03e-05	0.000558	CcSEcCtD
Ziprasidone—Weight increased—Prednisone—chronic obstructive pulmonary disease	8.03e-05	0.000558	CcSEcCtD
Ziprasidone—Headache—Arformoterol—chronic obstructive pulmonary disease	7.99e-05	0.000555	CcSEcCtD
Ziprasidone—Headache—Formoterol—chronic obstructive pulmonary disease	7.99e-05	0.000555	CcSEcCtD
Ziprasidone—Weight decreased—Prednisone—chronic obstructive pulmonary disease	7.98e-05	0.000555	CcSEcCtD
Ziprasidone—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	7.98e-05	0.000554	CcSEcCtD
Ziprasidone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	7.96e-05	0.000553	CcSEcCtD
Ziprasidone—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	7.96e-05	0.000553	CcSEcCtD
Ziprasidone—Vomiting—Montelukast—chronic obstructive pulmonary disease	7.94e-05	0.000552	CcSEcCtD
Ziprasidone—Rash—Montelukast—chronic obstructive pulmonary disease	7.88e-05	0.000547	CcSEcCtD
Ziprasidone—Dermatitis—Montelukast—chronic obstructive pulmonary disease	7.87e-05	0.000547	CcSEcCtD
Ziprasidone—Headache—Montelukast—chronic obstructive pulmonary disease	7.83e-05	0.000544	CcSEcCtD
Ziprasidone—Angioedema—Prednisolone—chronic obstructive pulmonary disease	7.73e-05	0.000537	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.000536	CcSEcCtD
Ziprasidone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	7.66e-05	0.000532	CcSEcCtD
Ziprasidone—Vertigo—Prednisolone—chronic obstructive pulmonary disease	7.6e-05	0.000528	CcSEcCtD
Ziprasidone—Rash—Salbutamol—chronic obstructive pulmonary disease	7.59e-05	0.000527	CcSEcCtD
Ziprasidone—Syncope—Prednisolone—chronic obstructive pulmonary disease	7.59e-05	0.000527	CcSEcCtD
Ziprasidone—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	7.59e-05	0.000527	CcSEcCtD
Ziprasidone—Nausea—Arformoterol—chronic obstructive pulmonary disease	7.58e-05	0.000526	CcSEcCtD
Ziprasidone—Nausea—Formoterol—chronic obstructive pulmonary disease	7.58e-05	0.000526	CcSEcCtD
Ziprasidone—Headache—Salbutamol—chronic obstructive pulmonary disease	7.54e-05	0.000524	CcSEcCtD
Ziprasidone—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	7.44e-05	0.000517	CcSEcCtD
Ziprasidone—Nausea—Montelukast—chronic obstructive pulmonary disease	7.42e-05	0.000515	CcSEcCtD
Ziprasidone—Hypertension—Prednisolone—chronic obstructive pulmonary disease	7.31e-05	0.000507	CcSEcCtD
Ziprasidone—Bradycardia—Prednisone—chronic obstructive pulmonary disease	7.19e-05	0.000499	CcSEcCtD
Ziprasidone—Nausea—Salbutamol—chronic obstructive pulmonary disease	7.15e-05	0.000497	CcSEcCtD
Ziprasidone—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	7.1e-05	0.000493	CcSEcCtD
Ziprasidone—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	7.06e-05	0.000491	CcSEcCtD
Ziprasidone—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	6.94e-05	0.000482	CcSEcCtD
Ziprasidone—Shock—Prednisolone—chronic obstructive pulmonary disease	6.8e-05	0.000472	CcSEcCtD
Ziprasidone—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	6.74e-05	0.000468	CcSEcCtD
Ziprasidone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	6.68e-05	0.000464	CcSEcCtD
Ziprasidone—Eye disorder—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.000459	CcSEcCtD
Ziprasidone—Angiopathy—Prednisone—chronic obstructive pulmonary disease	6.41e-05	0.000445	CcSEcCtD
Ziprasidone—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000443	CcSEcCtD
Ziprasidone—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	6.31e-05	0.000438	CcSEcCtD
Ziprasidone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	6.25e-05	0.000434	CcSEcCtD
Ziprasidone—Alopecia—Prednisone—chronic obstructive pulmonary disease	6.24e-05	0.000434	CcSEcCtD
Ziprasidone—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	6.2e-05	0.000431	CcSEcCtD
Ziprasidone—Mental disorder—Prednisone—chronic obstructive pulmonary disease	6.19e-05	0.00043	CcSEcCtD
Ziprasidone—Erythema—Prednisone—chronic obstructive pulmonary disease	6.15e-05	0.000427	CcSEcCtD
Ziprasidone—Malnutrition—Prednisone—chronic obstructive pulmonary disease	6.15e-05	0.000427	CcSEcCtD
Ziprasidone—Vision blurred—Prednisone—chronic obstructive pulmonary disease	5.8e-05	0.000403	CcSEcCtD
Ziprasidone—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	5.69e-05	0.000395	CcSEcCtD
Ziprasidone—Anaemia—Prednisone—chronic obstructive pulmonary disease	5.68e-05	0.000395	CcSEcCtD
Ziprasidone—Agitation—Prednisone—chronic obstructive pulmonary disease	5.65e-05	0.000393	CcSEcCtD
Ziprasidone—Angioedema—Prednisone—chronic obstructive pulmonary disease	5.62e-05	0.00039	CcSEcCtD
Ziprasidone—Vertigo—Prednisone—chronic obstructive pulmonary disease	5.53e-05	0.000384	CcSEcCtD
Ziprasidone—Syncope—Prednisone—chronic obstructive pulmonary disease	5.51e-05	0.000383	CcSEcCtD
Ziprasidone—Urticaria—Prednisolone—chronic obstructive pulmonary disease	5.49e-05	0.000381	CcSEcCtD
Ziprasidone—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	5.4e-05	0.000375	CcSEcCtD
Ziprasidone—Hypertension—Prednisone—chronic obstructive pulmonary disease	5.31e-05	0.000369	CcSEcCtD
Ziprasidone—Myalgia—Prednisone—chronic obstructive pulmonary disease	5.24e-05	0.000364	CcSEcCtD
Ziprasidone—Arthralgia—Prednisone—chronic obstructive pulmonary disease	5.24e-05	0.000364	CcSEcCtD
Ziprasidone—Anxiety—Prednisone—chronic obstructive pulmonary disease	5.22e-05	0.000362	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	5.2e-05	0.000361	CcSEcCtD
Ziprasidone—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	5.09e-05	0.000353	CcSEcCtD
Ziprasidone—Infection—Prednisone—chronic obstructive pulmonary disease	4.99e-05	0.000346	CcSEcCtD
Ziprasidone—Shock—Prednisone—chronic obstructive pulmonary disease	4.94e-05	0.000343	CcSEcCtD
Ziprasidone—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	4.92e-05	0.000342	CcSEcCtD
Ziprasidone—Tachycardia—Prednisone—chronic obstructive pulmonary disease	4.9e-05	0.00034	CcSEcCtD
Ziprasidone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	4.87e-05	0.000339	CcSEcCtD
Ziprasidone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	4.85e-05	0.000337	CcSEcCtD
Ziprasidone—Anorexia—Prednisone—chronic obstructive pulmonary disease	4.78e-05	0.000332	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	4.57e-05	0.000318	CcSEcCtD
Ziprasidone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	4.57e-05	0.000317	CcSEcCtD
Ziprasidone—Insomnia—Prednisone—chronic obstructive pulmonary disease	4.54e-05	0.000315	CcSEcCtD
Ziprasidone—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	4.51e-05	0.000313	CcSEcCtD
Ziprasidone—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	4.42e-05	0.000307	CcSEcCtD
Ziprasidone—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	4.36e-05	0.000303	CcSEcCtD
Ziprasidone—Rash—Prednisolone—chronic obstructive pulmonary disease	4.35e-05	0.000302	CcSEcCtD
Ziprasidone—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	4.35e-05	0.000302	CcSEcCtD
Ziprasidone—Fatigue—Prednisone—chronic obstructive pulmonary disease	4.33e-05	0.000301	CcSEcCtD
Ziprasidone—Headache—Prednisolone—chronic obstructive pulmonary disease	4.33e-05	0.000301	CcSEcCtD
Ziprasidone—Constipation—Prednisone—chronic obstructive pulmonary disease	4.29e-05	0.000298	CcSEcCtD
Ziprasidone—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	4.14e-05	0.000287	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	4.1e-05	0.000285	CcSEcCtD
Ziprasidone—Nausea—Prednisolone—chronic obstructive pulmonary disease	4.1e-05	0.000285	CcSEcCtD
Ziprasidone—Urticaria—Prednisone—chronic obstructive pulmonary disease	3.99e-05	0.000277	CcSEcCtD
Ziprasidone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	3.97e-05	0.000276	CcSEcCtD
Ziprasidone—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.97e-05	0.000276	CcSEcCtD
Ziprasidone—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	3.7e-05	0.000257	CcSEcCtD
Ziprasidone—Asthenia—Prednisone—chronic obstructive pulmonary disease	3.6e-05	0.00025	CcSEcCtD
Ziprasidone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	3.43e-05	0.000239	CcSEcCtD
Ziprasidone—Dizziness—Prednisone—chronic obstructive pulmonary disease	3.32e-05	0.000231	CcSEcCtD
Ziprasidone—Vomiting—Prednisone—chronic obstructive pulmonary disease	3.19e-05	0.000222	CcSEcCtD
Ziprasidone—Rash—Prednisone—chronic obstructive pulmonary disease	3.16e-05	0.00022	CcSEcCtD
Ziprasidone—Dermatitis—Prednisone—chronic obstructive pulmonary disease	3.16e-05	0.00022	CcSEcCtD
Ziprasidone—Headache—Prednisone—chronic obstructive pulmonary disease	3.14e-05	0.000218	CcSEcCtD
Ziprasidone—Nausea—Prednisone—chronic obstructive pulmonary disease	2.98e-05	0.000207	CcSEcCtD
Ziprasidone—CHRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.37e-06	5.72e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.37e-06	5.72e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.36e-06	5.7e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.34e-06	5.68e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.34e-06	5.68e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.33e-06	5.67e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.33e-06	5.66e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.32e-06	5.65e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.31e-06	5.64e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.31e-06	5.64e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.3e-06	5.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.3e-06	5.63e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.22e-06	5.52e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.18e-06	5.47e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.16e-06	5.45e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.15e-06	5.43e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.14e-06	5.41e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.13e-06	5.41e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.13e-06	5.4e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.13e-06	5.4e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.12e-06	5.39e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.1e-06	5.37e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.1e-06	5.37e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.1e-06	5.36e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—ALB—chronic obstructive pulmonary disease	4.08e-06	5.34e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.07e-06	5.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.05e-06	5.3e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.02e-06	5.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4e-06	5.23e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.99e-06	5.22e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.98e-06	5.21e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.97e-06	5.2e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.95e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.95e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.93e-06	5.15e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.92e-06	5.13e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—NOS3—chronic obstructive pulmonary disease	3.91e-06	5.11e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.9e-06	5.1e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.89e-06	5.09e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.88e-06	5.08e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.86e-06	5.06e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.84e-06	5.03e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.81e-06	4.99e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.8e-06	4.98e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.79e-06	4.96e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.79e-06	4.96e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.76e-06	4.92e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	3.75e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.74e-06	4.89e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.73e-06	4.88e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.71e-06	4.85e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.71e-06	4.85e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.69e-06	4.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.69e-06	4.83e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.68e-06	4.82e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.67e-06	4.81e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.63e-06	4.75e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.63e-06	4.75e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.61e-06	4.73e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.61e-06	4.72e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.61e-06	4.72e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.6e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.59e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.58e-06	4.69e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	3.58e-06	4.69e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.56e-06	4.65e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.55e-06	4.64e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.55e-06	4.64e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.54e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.51e-06	4.59e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.51e-06	4.59e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.51e-06	4.59e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.5e-06	4.58e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.5e-06	4.58e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.49e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.45e-06	4.51e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.44e-06	4.51e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.44e-06	4.5e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	3.43e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.43e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.42e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.41e-06	4.46e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.4e-06	4.45e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.39e-06	4.43e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.38e-06	4.42e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.38e-06	4.42e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.38e-06	4.42e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.36e-06	4.4e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.35e-06	4.39e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.35e-06	4.38e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.34e-06	4.37e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.34e-06	4.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.33e-06	4.36e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.32e-06	4.35e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.31e-06	4.34e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.31e-06	4.33e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.29e-06	4.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.29e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.29e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	3.28e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.28e-06	4.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.27e-06	4.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.27e-06	4.27e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.26e-06	4.26e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.24e-06	4.25e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.23e-06	4.23e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.23e-06	4.23e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.23e-06	4.22e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.22e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.22e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.21e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.21e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.2e-06	4.19e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.19e-06	4.18e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.19e-06	4.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.17e-06	4.15e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.15e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.15e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.14e-06	4.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.11e-06	4.07e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.08e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.06e-06	4.01e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.06e-06	4e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.04e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.04e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.02e-06	3.95e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3e-06	3.92e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.97e-06	3.88e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.96e-06	3.87e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.93e-06	3.84e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.92e-06	3.82e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.92e-06	3.81e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.91e-06	3.81e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.91e-06	3.8e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.9e-06	3.79e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.89e-06	3.78e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.87e-06	3.76e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.87e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.86e-06	3.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.85e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.84e-06	3.71e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.82e-06	3.69e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.8e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.8e-06	3.66e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.78e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.78e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.77e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.76e-06	3.62e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.75e-06	3.6e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.75e-06	3.59e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.73e-06	3.57e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.73e-06	3.57e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.72e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.72e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.7e-06	3.53e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.69e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.68e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.66e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.66e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.66e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.64e-06	3.46e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.64e-06	3.46e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.64e-06	3.45e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.63e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.62e-06	3.43e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.62e-06	3.42e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.61e-06	3.42e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.59e-06	3.39e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.59e-06	3.39e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.57e-06	3.36e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.56e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.56e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.55e-06	3.33e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.53e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.53e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.52e-06	3.3e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.51e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.49e-06	3.26e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.48e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.47e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.46e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.45e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.44e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.44e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.42e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.41e-06	3.16e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.41e-06	3.16e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.4e-06	3.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.4e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.39e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.38e-06	3.12e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.37e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.37e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.36e-06	3.09e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.35e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.35e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.35e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.34e-06	3.06e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.33e-06	3.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.32e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.32e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.21e-06	2.9e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.21e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.18e-06	2.85e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.18e-06	2.85e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.17e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.17e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.17e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.16e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.16e-06	2.82e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.15e-06	2.81e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.14e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.14e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.13e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.13e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.12e-06	2.78e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.12e-06	2.77e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.1e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.09e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.08e-06	2.72e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.07e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.06e-06	2.7e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.01e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.98e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.98e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.98e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.97e-06	2.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.94e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.9e-06	2.49e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.89e-06	2.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.84e-06	2.4e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.82e-06	2.38e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.81e-06	2.37e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.79e-06	2.35e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.79e-06	2.34e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.78e-06	2.33e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.78e-06	2.33e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.76e-06	2.3e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.76e-06	2.3e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.67e-06	2.18e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.64e-06	2.15e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.64e-06	2.14e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.63e-06	2.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.63e-06	2.13e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.63e-06	2.13e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.61e-06	2.11e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.61e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.6e-06	2.09e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.53e-06	2e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.49e-06	1.95e-05	CbGpPWpGaD
